AstraZeneca’s Injectable Antibody Cocktail Halves Risk Of Death Or Developing Severe Covid, Trial Finds

The British pharma firm has already asked U.S. regulators for emergency approval to use the antibody cocktail to prevent symptomatic Covid-19.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive